chr11-108252851-G-T

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.

The NM_000051.4(ATM):​c.1837G>T​(p.Val613Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000422 in 1,612,816 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.000039 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000042 ( 0 hom. )

Consequence

ATM
NM_000051.4 missense

Scores

5
10
4

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:9

Conservation

PhyloP100: 7.85
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 0 ACMG points.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ATMNM_000051.4 linkuse as main transcriptc.1837G>T p.Val613Leu missense_variant 12/63 ENST00000675843.1 NP_000042.3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ATMENST00000675843.1 linkuse as main transcriptc.1837G>T p.Val613Leu missense_variant 12/63 NM_000051.4 ENSP00000501606 P1

Frequencies

GnomAD3 genomes
AF:
0.0000395
AC:
6
AN:
152038
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000883
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000319
AC:
8
AN:
250872
Hom.:
0
AF XY:
0.0000516
AC XY:
7
AN XY:
135606
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000617
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000424
AC:
62
AN:
1460778
Hom.:
0
Cov.:
30
AF XY:
0.0000372
AC XY:
27
AN XY:
726730
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000540
Gnomad4 OTH exome
AF:
0.0000166
GnomAD4 genome
AF:
0.0000395
AC:
6
AN:
152038
Hom.:
0
Cov.:
32
AF XY:
0.0000269
AC XY:
2
AN XY:
74268
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000883
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000901
Hom.:
0
Bravo
AF:
0.0000302
ExAC
AF:
0.0000412
AC:
5
EpiCase
AF:
0.0000545
EpiControl
AF:
0.0000593

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Uncertain:3
Uncertain significance, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthMay 11, 2023This missense variant replaces valine with leucine at codon 613 of the ATM protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. In a large international case-control study, this variant was reported in 9/60466 breast cancer cases and 1/53461 controls (OR=7.958, 95%CI 1.008 to 62.82, p-value=0.024; PMID: 33471991). This variant has been reported in additional individuals affected with breast cancer (PMID: 19781682, 20305132), an individual affected with breast cancer and mesothelioma (PMID: 34008015), and an individual affected with prostate cancer (PMID: 33436325). This variant has also been identified in 8/250872 chromosomes in the general population by the Genome Aggregation Database (gnomAD) and in one woman age 70 years or older without cancer (https://whi.color.com/variant/11-108123578-G-T). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Jun 03, 2021- -
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsApr 03, 2024The p.V613L variant (also known as c.1837G>T), located in coding exon 11 of the ATM gene, results from a G to T substitution at nucleotide position 1837. The valine at codon 613 is replaced by leucine, an amino acid with highly similar properties. This alteration was reported in 1 of 4112 breast cancer cases and in 0 of 2399 controls (Tavtigian SV Am. J. Hum. Genet. 2009 Oct; 85(4):427-46). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Ataxia-telangiectasia syndrome Uncertain:2
Uncertain significance, no assertion criteria providedclinical testingNatera, Inc.Mar 01, 2021- -
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 613 of the ATM protein (p.Val613Leu). This variant is present in population databases (rs200124136, gnomAD 0.004%). This missense change has been observed in individual(s) with breast cancer, prostate cancer and/or mesothelioma (PMID: 19781682, 33436325, 34008015). ClinVar contains an entry for this variant (Variation ID: 181922). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Familial cancer of breast Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsSep 06, 2023- -
Uncertain significance, no assertion criteria providedclinical testingZotz-Klimas Genetics Lab, MVZ Zotz KlimasOct 30, 2023- -
not specified Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoJan 04, 2021This sequence change has been previously described in a patient with breast cancer but no additional information was provided (PMID: 19781682). It has been described in the gnomAD database with a low population frequency of 0.0062% in the non-Finnish European subpopulation (dbSNP rs200124136). The p.Val613Leu change affects a moderately conserved amino acid residue located in a domain of the ATM protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Val613Leu substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Val613Leu change remains unknown at this time. -
not provided Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingGeneDxAug 22, 2024Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Observed in individuals with breast and other cancers, as well as in both cases and unaffected controls in a breast cancer study (PMID: 19781682, 25148578, 26689913, 26898890, 33471991, 33436325); This variant is associated with the following publications: (PMID: 25148578, 19781682, 26917275, 26689913, 23407552, 28873162, 26898890, 28652578, 31064868, 33782497, 33436325, 34008015, 33471991, 20305132, 38446987) -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.62
BayesDel_addAF
Uncertain
0.14
D
BayesDel_noAF
Uncertain
0.090
CADD
Uncertain
25
DANN
Uncertain
1.0
DEOGEN2
Benign
0.089
.;T;T
Eigen
Pathogenic
0.76
Eigen_PC
Pathogenic
0.77
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Uncertain
0.86
D;D;.
M_CAP
Uncertain
0.14
D
MetaRNN
Uncertain
0.47
T;T;T
MetaSVM
Uncertain
0.14
D
MutationAssessor
Uncertain
2.8
.;M;M
MutationTaster
Benign
1.0
D;D
PrimateAI
Uncertain
0.52
T
PROVEAN
Benign
-1.3
N;N;N
REVEL
Uncertain
0.41
Sift
Benign
0.032
D;D;D
Sift4G
Pathogenic
0.0
D;T;T
Polyphen
1.0
.;D;D
Vest4
0.82, 0.81
MutPred
0.39
Loss of catalytic residue at V613 (P = 0.0102);Loss of catalytic residue at V613 (P = 0.0102);Loss of catalytic residue at V613 (P = 0.0102);
MVP
0.95
MPC
0.16
ClinPred
0.49
T
GERP RS
5.7
Varity_R
0.50
gMVP
0.61

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs200124136; hg19: chr11-108123578; COSMIC: COSV53767212; API